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Idiopathic pulmonary fibrosis (IPF) is a lethal pulmonary disease which is characterized by
progressive fibrosis. In general, the exaggerated activation of the coagulation cascade has been
observed during initiation or maintenance of the fibrotic disease. In a recent study, protease-
activated receptor (PAR)-2, which plays a key role in coagulation cascade, was up-regulated
in IPF patients, however, its clinical implications have not been understood. The objective of
the present study was to evaluate the clinical significance of PAR-2 expression in the alveolar
epithelial cells of IPF patients. PAR-2 expressionwas evaluated by immunohistochemicalmethod
in formalin-fixed and paraffin-embedded tissues of surgical lung biopsies from patients with IPF.
Fibrosis scores from hematoxylin and eosin-stained lung sections and honeycombing scores in
chest CT were calculated. Medical records were retrospectively reviewed and the correlation
between the expression of PAR-2 and clinical profiles were assessed. Among thirty-three IPF
patients, PAR-2 expression was observed in 25 (75.8%). The lymphocyte counts in peripheral
blood (2317 vs. 1753, pZ 0.044) and honeycombing scores in chest CT (4.0 vs. 3.0 pZ 0.046)
were higher in PAR-2 positive group compared with PAR-2 negative group. During a follow-up
duration of median 40.3 months, 7 (21.2%) patients died and they were all included in the
PAR-2 positive group (pZ 0.113). We conclude that PAR-2 is expressed in the alveolar epithelial
cells of a substantial number of IPF patients, and the expression of PAR-2 significantly correlates
with the extent of honeycombing shown in chest CT.
ª 2012 Elsevier Ltd. All rights reserved.2072 3760; fax: þ82 2 762 9662.
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approved by institutional review board of Seoul NationalIdiopathic pulmonary fibrosis (IPF) is a lethal fibrotic lung
disease of unknown etiology. Unfortunately, it is a progres-
sive and irreversible disorder. In general, median survival of
IPF patients is 2.5e5 years with or without treatment.1
Even to this day, pathogenesis of IPF is poorly understood
and prognostic factor is not clearly defined.2 Various ther-
apeutic approaches, such as anti-inflammatory, immuno-
modulatory, and anti-fibrotic agents have been tried, but
effective treatment has not been established. Thus, new
insights into pathogenesis of IPF are essential for the
development of effective treatments.
One of the major advances in the pathogenesis of IPF is
the shift in current paradigms from inflammation to
abnormal wound healing.3,4 In the wound healing process,
the coagulation cascade is activated locally from the tissue
factor dependent extrinsic pathway.5 Recent studies
implicated that protease-activated receptor (PAR)-2 may
play a significant role in the pathogenesis of fibrosis. Factor
Xa-dependent PAR-2 activation showed a profibrotic
response in fibroblasts and caused lung fibrosis in an
experimental acute lung injury model.6 Furthermore, PAR-2
induced myofibroblast differentiation in a bleomycin-
induced pulmonary fibrosis model.7
PAR-2 is a G-coupled 7-transmembrane receptor that is
activated by tethered peptide ligand, which is exposed
after enzymatic cleavage of the specific site in the extra-
cellular N-terminal.8 PAR-2 is expressed in various tissues
and is found more in kidney, pancreas, and gastrointestinal
tissue than in heart and lungs.9 PAR-2 expression is mainly
located in endothelial and epithelial cells.10 In lungs, PAR-2
is highly expressed in ciliated and non-ciliated epithelial
cells.11 Recent studies suggested the association of PAR-2
activation with airway inflammation11e13 and pulmonary
fibrosis.7 In addition, up-regulation of PAR-2 was observed
in lung tissue of IPF patients and PAR-2 could be a signifi-
cant contributor in fibrotic process.14 These findings
suggest that PAR-2 expression may be associated with the
development of fibrosis in IPF. However, to our knowledge,
there are no previous studies reporting the relationship
between PAR-2 expression and the clinical parameters
implicating fibrosis. In this study, we investigated the
correlations between PAR-2 expression and the clinical
parameters for fibrosis, such as fibrosis scores in surgical
specimens and honeycombing scores in chest computed
tomography (CT), and all-cause mortality.Methods
Study population
Surgical lung biopsy-proven IPF patients in one tertiary
referral hospital in Seoul, Korea between January 2005 and
May 2010 were included in this study. The surgical biopsy
was performed at the time of initial diagnosis of IPF.
Pathologic diagnosis was based on the established criteria
and clinical diagnosis was made according to the interna-
tional guidelines.15 Medical records were reviewed retro-
spectively. The study protocol (H-1007-137-324) wasUniversity Hospital. The board waived informed consent
from participants. This study was conducted in accordance
with the Declaration of Helsinki.
Fibrosis score
The slides of hematoxylin and eosin-stained lung sections
were reviewed by two independent board certified
pathologists to score fibrosis. In brief, the whole lung
section of each slide was observed to assess the area of
fibrosis using light microscopy (Olympus Optical Co. Ltd.,
Tokyo, Japan). The extent of fibrotic lesions was scored as 0
(0e10%), 1 (10e25%), 2 (25e50%), 3 (50e75%), or 4
(75e100%). The severity of fibrosis was scored from
0 (normal lung) to 8 (total fibrosis) according to Ashcroft
scoring system16 at a magnification of 200 in average of 10
different fields. Finally, fibrosis scores were calculated by
multiplying the extent of fibrotic lesion to Ashcroft scores.
A mean value of the scores from two pathologists was
considered as the final fibrosis score.
Honeycombing score
Honeycombing on chest CT image was defined as thick-
walled air-filled cysts between the sizes of several milli-
meters to several centimeters in diameter. Previous
method shown by Akira et al.17 was used to assess the
honeycombing score by two independent board certified
pulmonary radiologists. In brief, the whole lung was divided
into six lobes (right upper, right middle, right lower, left
upper, lingular division, and left lower lobe) and the extent
of honeycombing lesion was assessed as 0 (absent), 1
(0e25%), 2 (25e50%), 3 (50e75%), or 4 (>75%) in each lobe.
Honeycombing score was the final sum of all six lobes. A
mean value of the scores from two radiologists was
considered as the final honeycombing score.
Immunohistochemical staining
Formalin-fixed and paraffin-embedded surgical lung biop-
sies of IPF patients were used for immunohistochemical
staining. After deparaffinization in xylene and rehydration
through graded alcohol to water, these slides were soaked
in Target Retrieval Solution (Dako, Carpenteria, CA, USA),
then placed under 60 C water bath for 20 min for antigen
retrieval. We used 1% H2O2 in methanol to quench endog-
enous peroxidase activity. The 1:50 goat polyclonal anti-
PAR-2 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) was added at 4 C overnight. The secondary antibody,
1:200 biotinylated anti-goat antibody (Vector, Burlingame,
CA, USA), was placed on the slides for 1 h at room
temperature. After brief washing in Tris-buffered saline,
Vectastain avidinebiotin complex elite kit (Vector, Burlin-
game, CA, USA) was applied for 1 h. Reaction products were
visualized using 3,3-diaminobenzidinetetrahydrochloride.
After washing with distilled water, counter staining was
performed with hematoxylin. Human pancreas tissue was
used for positive and negative control.18 Negative control
was performed with the same protocol but without the
primary antibody. Positive immunohistochemical staining of
258 Y.S. Park et al.PAR-2 was defined as 20% or more of brown staining of PAR-
2 shown in the alveolar epithelial cells (Fig. 1).
All-cause mortality
The all-cause mortality data were obtained from the
Ministry of Public Administration and Security using the
social number of each patient. The queried results were
composed of whether the patient was alive or not, and the
date of death.
Statistics
We analyzed PAR-2 expression and the patients’ clinical
characteristics by c2-test or Fisher’s exact test using SPSS
version 19 (SPSS Inc., Chicago, IL, USA) statistical software
package. ManneWhitney U-test was used for comparison of
means between PAR-2 positive and negative groups.
KaplaneMeier curve was plotted for survival analysis, and
log rank test was used for p-value. A value of p < 0.05 was
considered to be significant.
Results
Baseline characteristics
Thirty-three (male 16, female 17) patients with surgical
lung biopsy-proven IPF were included in this study. The
median age was 62 (range, 38e74) years. About 61% of
these patients (n Z 20) had never smoked and a medianFigure 1 Immunohistochemical staining of protease-activated re
fibrosis patients. PAR-2 expression of alveolar epithelial cells ove
(arrow in b) is observed. Figure c is PAR-2 negative case and Figurfollow-up duration was 40.3 (range, 4.9e74.9) months
(Table 1). The median forced vital capacity (FVC), forced
expiratory volume in 1 s (FEV1), and carbon monoxide
diffusion capacity (DLCO) were 72.0%, 84.0% and 58.0%,
respectively. The most common findings in chest CT were
honeycombing (100%) and ground glass opacity (66.7%).
During a median follow-up of 40.3 (range, 4.9e74.9)
months, 26 patients (78.8%) survived.
Clinical characteristics according to PAR-2
expression
PAR-2 was expressed in 25 (75.8%) patients. The clinical
characteristics including arterial blood gas analysis and
pulmonary function test were not different between PAR-2
positive and negative group (Table 2).
Profiles of inflammatory cells according to PAR-2
expression
The profiles of inflammatory cells in peripheral blood
(n Z 33) and bronchoalveolar lavage fluid (BALF) (n Z 15)
were analyzed. In PAR-2 positive group, blood neutrophil
counts were lower and lymphocytes counts were higher
than in PAR-2 negative group (Fig. 2a and b). Blood mono-
cyte counts were lower in PAR-2 positive group but the
difference was not statistically significant (Fig. 2c).
Although the number of BALF samples was small, the
profiles of inflammatory cells in BALF were similar to the
pattern shown in peripheral blood (Fig. 2def). The ratio ofceptor (PAR)-2 in surgical lung biopsies of idiopathic pulmonary
rlying fibroblastic foci (asterisk in a) and inflammatory lesion
e d is positive control (human pancreas tissue).
Table 1 Baseline characteristics of 33 idiopathic pulmo-
nary fibrosis patients.
Variables Values
Age, (median, range), years 62 (38e74)
Male sex (%) 16 (48.5%)
Smoking state
Never smoker 20 (60.6%)
Ex-smoker 9 (27.3%)
Current smoker 4 (12.1%)
Follow-up duration,
(median, range), months
40.3 (4.9e74.9)
Arterial blood gas analysis (n Z 31)
pH (median, range) 7.41 (7.36e7.49)
PaO2 (median, range), mmHg 88.6 (57.5e142.0)
PCO2 (median, range), mmHg 40.9 (27.2e47.3)
Saturation (median, range), % 96.9 (89.6e99.0)
White blood cell count
(median, range) (/mm3)
7600 (3910e11,820)
Neutrophil (median, range)
(/mm3)
3689 (1439e6882)
Lymphocyte
(median, range) (/mm3)
2113 (759e4255)
Pulmonary function test (n Z 32)
FVC (median, range), % 72.0% (51e104)
FEV1 (median, range), % 84.0% (60e109)
FEV1/FVC (median, range), % 85.5% (70e98)
DLCO (median, range), %
(n Z 31)
58.0% (35e154)
Radiologic features
Ground glass opacity (%) 22 (66.7%)
Reticular density (%) 10 (30.3%)
Aircyst (%) 5 (15.2%)
Consolidation (%) 3 (9.1%)
Nodular thickening (%) 1 (3.0%)
Traction bronchiectasis (%) 1 (3.0%)
Honeycombing (%) 33 (100%)
Survivors (%) 26 (78.8%)
FVC: forced vital capacity; FEV1: forced expiratory volume in
1 s; DLCO: carbon monoxide diffusion capacity.
PAR-2 expression in idiopathic pulmonary fibrosis 259bacterial isolation in BALF was not different according to
PAR-2 expression (Table 2).
Associations of PAR-2 expression with fibrosis and
honeycombing score
Honeycombing scores which were calculated from chest CT
were higher in PAR-2 positive group than in PAR-2 negative
group (p Z 0.046) (Fig. 3). There was a same trend of
increased fibrosis scores in PAR-2 positive group, but the
difference was not statistically significant.
All-cause mortality
During a median follow-up period of 40.3 (range, 4.9e74.9)
months, 26 patients (78.8%) survived. All 7 fatal cases were
in the PAR-2 positive group, but the difference did not
reach statistical significance (Fig. 4).Discussion
The understanding of IPF pathogenesis has shifted from
inflammatory response to aberrant wound healing of
unknown etiology.3,4 In other words, the pulmonary fibrosis is
considered as the common end pathway of aberrant wound
healing. Interestingly, coagulation cascade activation was
frequently observed during thefibrotic process not only in IPF
but also in other inflammatory conditions such as systemic
sclerosis and acute respiratory distress syndrome.19,20 In an
acute lung injury animal model, uncontrolled activation of
coagulation cascade and pulmonary fibrosis was observed,
and PAR-2 activated by Factor Xa was a significant receptor
for the development of pulmonary fibrosis.7 These findings
suggest the possible role of PAR-2 in the pathogenesis or
progression of pulmonary fibrosis.
The relationship between PAR-2 expression and fibrosis
itself was previously disclosed in many other tissues, such
as pancreas,21 kidney,22 and liver.23 In the context of PAR-2
expression and fibrosis, the authors assessed whether PAR-2
is expressed in lung tissue from IPF patients. In the litera-
ture review, there were 2 papers on PAR-2 immunohisto-
chemical expression in the smooth muscle cells, epithelial
cells, and fibroblasts/myofibroblast in lung biopsies of
patients with IPF.7,14 Both of them suggested a significant
role of PAR-2 activation and it’s consequence of coagulation
cascade in pulmonary fibrotic process. In our data, PAR-2
expression of alveolar epithelial cells was significantly
associated with honeycombing score on chest CT, and our
result support the contributable role of PAR-2 in pulmonary
fibrosis.
In our cohort, there was no statistically significant
difference in smoking status, but current smokers were
found only in PAR-2 positive group (Table 2). In the litera-
ture, a significant increase of PAR-2 expression has been
observed in bronchial vessels of smokers with chronic
bronchitis but no airway obstruction11 and in the epithelium
of asthmatic patients.24 Using alveolar macrophage in BAL
fluid, PAR-2 mRNA was increased in smokers.25 Our findings
are consistent with these results in the context of smoking-
induced airway inflammation. But the association between
PAR-2 expression in the alveolar epithelial cells and
smoking is still unclear.
The PAR-2 positive group showed lower neutrophil and
higher lymphocyte count in peripheral blood, and this
phenomenon was also observed in BALF (Fig. 2). The ratio
of bacterial isolation in BALF was not different between
PAR-2 positive and negative groups. The meaning of these
findings is not clearly understood. BALF analysis in patients
with IPF shows increased polymorphonuclear leukocytes,
neutrophil products, activated macrophages, cytokines,
and chemokines.26 The presence of lymphocytes in the
fibrotic lung tissue is common finding in IPF. But there are
only few data on the trends of inflammatory cell profiles in
the disease progression of IPF. Parra et al.27 reported that
the increased cell density of CD3 positive lymphocyte in the
area of fibrotic lung tissues correlates with the worse
clinical outcome in IPF. Ramelli et al.28 demonstrated pro-
inflammatory effect of PAR-2 on T lymphocytes in animal
inflammation model. Boveda-Ruiz et al.29 reported the
detrimental role of T lymphocytes in late stage of pulmo-
nary fibrosis using bleomycin-induced lung fibrosis in mice
Table 2 Clinical variables and the expression of protease-activated receptor-2 (PAR-2) expression in surgical lung biopsies of
idiopathic pulmonary fibrosis patients.
Variables PAR-2 positive (n Z 25) PAR-2 negative (n Z 8) p-value
Age, (median, range), years 62 (38e72) 59 (38e74) 0.674
Male sex (%) 14 (56.0%) 2 (25.0%) 0.225
Current smoker 4 (16.0%) 0 (0%) 0.550
Follow-up duration,
(median, range), months
39.8 (4.9e74.3) 43.5 (15.45e74.9) 0.556
Arterial blood gas analysis (n Z 31)
pH (median, range) 7.41 (7.36e7.49) 7.42 (7.40e7.45) 0.331
PaO2 (median, range), mmHg 88.6 (57.5e142.0) 89.1 (76.9e96.3) 0.685
PaCO2 (median, range), mmHg 40.2 (32.8e47.3) 41.6 (27.2e46.4) 0.804
Saturation (median, range), % 96.9 (89.6e99.0) 97.0 (95.1e98.0) 0.804
Pulmonary function test (n Z 32)
FVC, (median, range), % 72 (51e104) 71.0 (62e90) 0.727
DLCO, (median, range), % 55.0 (35e154) 59.0 (39e83) 0.964
Bronchoalveolar lavage (n Z 18)
Bacterial isolation 9/13 (69.2%) 4/5 (80%) 1.000
FVC: forced vital capacity; DLCO: carbon monoxide diffusion capacity.
ManneWhitney U-test was used for continuous variables and c2 test for categorical variables.
260 Y.S. Park et al.model. Considering cross-regulation between inflammation
and fibrosis in IPF,30 T lymphocytes activated by PAR-2
could result in fibrosis. It is possible to postulate that
lymphocyte may be an important inflammatory cell in
advanced fibrotic stage of IPF.
The authors observed that the expression of PAR-2 was
associated with the extent of fibrosis shown in chest CT
(Fig. 3a). In this study, higher honeycombing scores wereFigure 2 Box plots of inflammatory cells in peripheral blood (aec
patients) based on the expression of protease-activated receptor (P
patients (25 in bloods and 15 in BAL fluids), neutrophils were decre
were increased in blood (b and c) and BAL fluid (e and f). ManneWobserved in PAR-2 positive group and there was a tendency
of increased tissue fibrosis scores in PAR-2 positive patients.
The reasons for non-significant differences found in tissue
fibrosis scores, are probably due to small sample size and
the limitation of the surgical lung biopsies to be considered
as a representative of total fibrosis. During surgical lung
biopsy, surgeons tend to avoid sampling in end stage fibrotic
lesion, the honeycombing area. So in the concept of overall, 33 patients) and bronchoalveolar lavage fluid (BALF) (def, 15
AR)-2 in idiopathic pulmonary fibrosis patients. In PAR-2 positive
ased in blood (a) and BAL fluid (d), lymphocytes and monocytes
hitney U-test was used for p-value.
Figure 3 Box plots of honeycombing and fibrosis scores based on protease-activated receptor (PAR)-2 expression. PAR-2 positive
patients showed advanced honeycombing lesion in chest CT (p Z 0.046) compare to PAR-2 negative patients (a). There was
a tendency to increased fibrosis scores in PAR-2 positive patients, but the difference was not statistically significant (p Z 0.313).
ManneWhitney U-test was used for p-value.
PAR-2 expression in idiopathic pulmonary fibrosis 261estimation in fibrosis, honeycombing score is the better
surrogate marker than fibrosis score of the selected tissues.
To the best of our knowledge, this study is the first
description of the correlation between immunohisto-
chemical expression of PAR-2 in surgical lung biopsies and
the clinical variables of IPF patients including survival
analysis. But our study has some limitations. First of all,
the study sample size was small, so it was difficult to
clarify the correlation between PAR-2 expression and
clinical variables with sufficient statistical power. Since
surgical lung biopsy is not essential to diagnosis of IPF, the
shortage of the surgical specimens was inevitable.31
Second, the follow-up duration was not long enough toFigure 4 KaplaneMeier curve of idiopathic pulmonary
fibrosis patients based on the expression of protease-activated
receptor (PAR)-2. All patients with PAR-2 negative group were
survived, compared to 7 non-survivors in PAR-2 positive group.
Log rank test was used for p-value.adequately evaluate survival differences, thus the impact
of PAR-2 expression on survival was not conclusive. Third,
there was no normal control, so we could not evaluate the
difference of PAR-2 expression between IPF patient and
healthy individual.
In conclusion, about three quarters of IPF patients in our
tertiary hospital cohort had PAR-2 expression in the alve-
olar epithelial cells, and the expression of PAR-2 signifi-
cantly correlates with honeycombing shown in chest CT.Acknowledgments
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